FDA halts Allogene CAR-T trial after safety scareA phase 1 trial of Allogene’s of-the-shelf CAR-T for lymphoma has been placed on hold by the FDA, Share XFDA halts Allogene CAR-T trial after safety scarehttps://pharmaphorum.com/news/fda-halts-allogene-car-t-trial-after-safety-scare/
Takeda halts trial of orexin drug in narcolepsy on safety groundsJapanese drugmaker Takeda has suspended dosing in phase 2 trials of its orexin agonist TAK-994, saying it had Share XTakeda halts trial of orexin drug in narcolepsy on safety groundshttps://pharmaphorum.com/news/takeda-halts-trial-of-orexin-drug-in-narcolepsy-on-safety-grounds/
Astellas reports fourth death in halted gene therapy trialThere has been a fourth patient fatality in Astellas’ clinical trial of its AT132 gene therapy for the Share XAstellas reports fourth death in halted gene therapy trialhttps://pharmaphorum.com/news/astellas-reports-fourth-death-in-halted-gene-therapy-trial/
FDA slaps clinical hold on BioMarin’s PKU gene therapyBioMarin Pharma has had another setback in its gene therapy development programme, announcing this morning that the FDA Share XFDA slaps clinical hold on BioMarin’s PKU gene therapyhttps://pharmaphorum.com/news/fda-slaps-clinical-hold-on-biomarins-pku-gene-therapy/
FDA firms up JAK inhibitor warnings after Xeljanz reviewThe FDA has concluded its safety review of Pfizer’s JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings Share XFDA firms up JAK inhibitor warnings after Xeljanz reviewhttps://pharmaphorum.com/news/fda-firms-up-jak-inhibitor-warnings-after-xeljanz-review/
More trouble for Astellas as AT132 gene therapy trial is halted againAstellas has halted dosing in a study of its AT132 gene therapy for the rare disease X-linked myotubular Share XMore trouble for Astellas as AT132 gene therapy trial is halted againhttps://pharmaphorum.com/news/more-trouble-for-astellas-as-at132-gene-therapy-trial-is-halted-again/
AZ says second COVID jab dose isn’t linked to rare clot reactionA new analysis has suggested that the rare blood clot side effects linked to AstraZeneca’s COVID-19 vaccine Vaxzevria Share XAZ says second COVID jab dose isn’t linked to rare clot reactionhttps://pharmaphorum.com/news/az-says-second-covid-jab-dose-isnt-linked-to-rare-clot-reaction/
AZ, J&J tweaking COVID shots to reduce clotting risks; reportAstraZeneca and Johnson & Johnson are both exploring ways to modify their COVID-19 vaccines to minimise the risk Share XAZ, J&J tweaking COVID shots to reduce clotting risks; reporthttps://pharmaphorum.com/news/az-jj-covid-vaccine-reduce-clotting-risks/
FDA adds warning of rare neurological side effect to J&J COVID jabThe FDA has added a new warning on the Johnson & Johnson COVID-19 vaccine, saying the shot has Share XFDA adds warning of rare neurological side effect to J&J COVID jabhttps://pharmaphorum.com/news/fda-adds-warning-of-rare-neurological-side-effect-to-jj-covid-jab/
